RT Journal Article
SR Electronic
T1 Anticarcinogenic effects from plasma elderly trained: the role of mitochondrial function
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.08.21263280
DO 10.1101/2021.09.08.21263280
A1 Peres, Alessandra
A1 Dorneles, Gilson Pires
A1 Branchini, Gisele
A1 Bordignon, Fernanda
A1 Romão, Pedro R T
A1 Minuzzi, Luciele
A1 Lira, Fabio S
A1 Cavalcante, Mateus
A1 Elsner, Viviane
YR 2021
UL http://medrxiv.org/content/early/2021/09/12/2021.09.08.21263280.abstract
AB This study aimed to evaluate the effects of a multimodal exercise training on systemic cytokine levels of the elderly, and the impact of post-exercise training plasma on prostate cancer cell viability and proliferation in vitro. Fasting blood samples were collected from eight institutionalized elderly before and after eight weeks of multimodal exercise training (twice a week). The levels of interleukin(IL)-1ra, IL-1β, IL-2, IL-6, IL-10, IL-17, interferon (IFN)-α, tumor necrosis factor (TNF)-α, fibroblast growth factor (FGF)-1, platelet-derived growth factor (PDGF) and transforming growth factor (TGF)-α were evaluated in the peripheral blood. PC3 prostate cancer cell lines were incubated with 10% plasma acquired before and after exercise training from each participant. Multimodal exercise training increased the plasma levels of IL-2, IL-10, IFN-α, and FGF-1, and decreased TNF-α concentrations. PC3 cells presented decreased cell viability evaluated by MTT and lactate dehydrogenase activity as well as lower rates of cell proliferation after the incubation with post-training plasma samples. Furthermore, the incubation of PC-3 cells with post-training plasma decreased the mitochondrial membrane polarization and increased mitochondrial reactive oxygen species (ROS) production without changes in cytosolic ROS. Post-training plasma did not change apoptosis or necrosis rates in the PC-3 cell line. In conclusion, we showed that systemic adaptations in plasma mediators of institutionalized elderly might alter cell viability and proliferation by targeting mitochondrial ROS in a prostate cancer cell line.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded, in part, with support from the FAPERGS, CAPES Finance Code 001, CNPq and Federal University of Health Sciences of Porto Alegre. GPD is recipient of a PNPD/CAPES fellowship. AP, FSL, and PRTR is Research Career Awardees of the CNPq. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Research Committee of Centro Universitario Metodista-IPA, Brazil approved the current study number 3.376.078). All participants signed written informed before enrollment and all procedures was in conformity with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available when requested.